Completed PHASE2 INTERVENTIONAL 3-arm NCT01498328

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma (ReACT)

A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Sponsor: Celldex Therapeutics

Conditions Giant Cell Glioblastoma Glioblastoma Glioblastoma With Oligodendroglial Component Gliosarcoma Recurrent Glioblastoma Relapsed Glioblastoma Small Cell Glioblastoma

Interventions Bevacizumab KLH Rindopepimut (CDX-110) with GM-CSF

Updated 10 times since 2017 Last updated: Feb 12, 2020 Started: Dec 31, 2011 Primary completion: Apr 30, 2015 Completion: May 17, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01498328, this PHASE2 trial focuses on Giant Cell Glioblastoma and Glioblastoma and remains completed. Sponsored by Celldex Therapeutics, it has been updated 10 times since 2011, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Mar 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Mar 2020 [monthly]

Completed PHASE2
Mar 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Mar 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celldex Therapeutics

Data source: Celldex Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Amherst, United States , Ann Arbor, United States , Atlanta, United States , Aurora, United States , Austin, United States , Baltimore, United States , Birmingham, United States , Boston, United States , Chicago, United States and 30 more locations